Individual results may vary, and treatment should be personalized based on medical history, current health status, and individual goals
The science of Microdosing GLP-1 Broad clinical potential: Commonly used to treat type 2 diabetes and weight management, GLP-1 medications act on GLP-1 receptors located in the brain, gut, and immune system, impacting multiple biomarkers. Recent studies have begun exploring low doses of GLP-1 medications for broader health goals beyond glucose control and weight loss. Emerging research in healthspan and longevity: In a series of studies, low doses of GLP-1 receptor agonists were shown to modulate inflammatory pathways, support mitochondrial function, and lower the risk of cognitive decline in study participantsgiving Microdosing GLP-1 promising potential for extending healthspan
Visceral fat reduction is especially valuable because this fat depot is strongly associated with metabolic dysfunction and health risks
Ipamorelin and GHRP-2 both effectively stimulate the natural production of growth hormone, while CJC-1295 No DAC amplifies this effect by increasing growth hormone secretion in short bursts
